Trolamine (Biafine)

ApprovedSmall molecule

Trolamine (Biafine) is one of 70 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal CarcinomaActive, not recruiting

VaginitisActive, not recruiting

DermatitisActive, not recruiting

Nasopharyngeal CarcinomaPhase 2

Active, not recruiting

VaginitisApproved

Active, not recruiting

DermatitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

282 competitors in Nasopharyngeal Carcinoma

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

34 2

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

21 3

Taxotere

AAvyxa

Phase 3

16 4

Tuoyi

SSun Yat-sen University

Phase 3

11 5

Theraplaza

BBiotech Pharmaceutical Co., Ltd.

Phase 3

10 6

Paraplatin

AAvyxa

Phase 3

4 7

Erbitux

IImclone

Phase 3

4 8

Adrucil

EElorac, Inc.

Phase 3

3 9

Celebrex

PPhiladelphia Eye Associates

Phase 3

1 10

Decadron

AAspen Global Incorporated

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Post-ApprovalNot yet recruiting

Vaginitis

NCT07492654

Clinical

Trials by Indication[1]

Vaginitis1 trial

Clinical Study on the Prevention and Treatment of Radiation Vaginitis With Triethanolamine Cream

Not yet recruiting·FFujian Cancer Hospital·Phase 4·NCT07492654·238 enrolled

Dermatitis1 trial

Efficacy of Fullerene in Preventing Radiation Dermatitis in Patients With Head and Neck Cancer .

Completed·WWest China Hospital·N/A·NCT06484166·132 enrolled

Nasopharyngeal Carcinoma1 trial

Comparison of Efficacy and Safety Between Medical Radiation Protectants (FORRAD®) and Trolamine (Biafine) for the Management of Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma Receiving IMRT

Unknown status·YYun-fei Xia·Phase 2·NCT02729324·136 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Trolamine (Biafine). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Trolamine (Biafine) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Trolamine (Biafine). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — West China Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: WWest China Hospital

Trolamine (Biafine)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Vaginitis1 trial

Dermatitis1 trial

Nasopharyngeal Carcinoma1 trial

References

Drug Info

Quick Facts

Related News